Daily Brief: GLP-1 Aging Signals and CO2 Energy Storage
This newsletter edition reports that Eli Lilly and Novo Nordisk say their GLP-1 weight-loss drugs may slow biological aging according to molecular aging clocks, though the meaning of those results is still debated. It also profiles Energy Dome, which stores renewable energy in large batteries that use compressed carbon dioxide. The issue additionally mentions OpenAI's new math findings and a narrated piece arguing that large language models do not reason.
Eli Lilly and Novo Nordisk report that patients on GLP-1 weight-loss medicines appear to age more slowly on molecular clocks that measure DNA or protein shifts. The companies suggest this hints at effects on aging itself, though researchers still question how much these markers mean.
Energy Dome stores renewable power in large batteries using compressed carbon dioxide. Unlike older compressed-air systems that rely on underground caverns, its design does not need particular geological conditions, which may make it easier to deploy across different grids. OpenAI also published 377 math results from an unreleased model, spanning several fields and costing less than earlier breakthroughs.
If these aging signals hold, GLP-1 drugs could shift preventive medicine and longevity research, affecting patients, clinicians, and drugmakers while raising regulatory questions. Energy Dome's approach may help grid operators integrate intermittent renewables, especially where underground storage is unavailable, potentially influencing utilities and ratepayers. OpenAI's math output could speed some discoveries and intensify debates about AI's role in research and whether LLMs truly reason. These developments may reshape expectations across health, energy, and computing, though their real-world effects remain uncertain.